Gilder Gagnon Howe & Co’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-12,247
Closed -$244K 259
2022
Q2
$244K Sell
12,247
-19,762
-62% -$399K ﹤0.01% 245
2022
Q1
$882K Sell
32,009
-41,911
-57% -$1.2M 0.01% 254
2021
Q4
$3.05M Sell
73,920
-6,918
-9% -$306K 0.02% 250
2021
Q3
$3.75M Sell
80,838
-1,625,802
-95% -$70.9M 0.02% 272
2021
Q2
$68.2M Sell
1,706,640
-690,141
-29% -$29.5M 0.33% 80
2021
Q1
$129M Sell
2,396,781
-567,454
-19% -$32.7M 0.69% 42
2020
Q4
$145M Sell
2,964,235
-113,465
-4% -$5.26M 0.72% 36
2020
Q3
$100M Sell
3,077,700
-89,879
-3% -$2.86M 0.62% 51
2020
Q2
$82M Sell
3,167,579
-398,097
-11% -$9.92M 0.64% 51
2020
Q1
$86.7M Sell
3,565,676
-206,283
-5% -$5.19M 1.04% 24
2019
Q4
$105M Sell
3,771,959
-52,667
-1% -$1.36M 1.09% 24
2019
Q3
$91.8M Sell
3,824,626
-46,825
-1% -$1.25M 1.05% 29
2019
Q2
$110M Buy
3,871,451
+418,227
+12% +$10.4M 1.11% 23
2019
Q1
$86.4M Buy
+3,453,224
New +$65.9M 0.92% 37
2016
Q1
Sell
-79,319
Closed -$571K 259
2015
Q4
$571K Sell
79,319
-46,601
-37% -$314K 0.01% 191
2015
Q3
$591K Sell
125,920
-932
-0.7% -$8.88K 0.01% 200
2015
Q2
$1.41M Sell
126,852
-2,774
-2% -$27.3K 0.02% 202
2015
Q1
$944K Sell
129,626
-558
-0.4% -$4.57K 0.01% 206
2014
Q4
$1.26M Sell
130,184
-242,275
-65% -$1.89M 0.02% 195
2014
Q3
$3.63M Sell
372,459
-65,410
-15% -$859K 0.05% 164
2014
Q2
$7.5M Buy
437,869
+29,242
+7% +$421K 0.1% 139
2014
Q1
$7M Buy
408,627
+10,635
+3% +$170K 0.1% 142
2013
Q4
$5.77M Buy
+397,992
New +$5.18M 0.08% 142

Other funds holding VCYT

Gilder Gagnon Howe & Co's VCYT Position: Q3 2022 in Review

Gilder Gagnon Howe & Co sold out of Veracyte (VCYT) in Q3 2022, closing a stake of 12,247 shares — an estimated $244K sold.

Gilder Gagnon Howe & Co first reported a position in VCYT in Q4 2013 and held it in 23 quarters. The position peaked at $145M in Q4 2020. 208 funds tracked by Wall St. Rank hold VCYT as of Q3 2022.

  • Gilder Gagnon Howe & Co reported no remaining Veracyte position as of Q3 2022 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 12,247 Veracyte shares in Q3 2022, an estimated $244K.
  • Gilder Gagnon Howe & Co first reported a position in Veracyte in Q4 2013 and held it in 23 quarters.
  • Gilder Gagnon Howe & Co's Veracyte position peaked at $145M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Veracyte as of Q3 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2022, filed 14 Nov 2022.